Drugs & Targets FDA Approves Opdivo for Urothelial Carcinoma Indication February 28, 2017Vol.40 No.02
Drugs & Targets FDA approves marketing of 23andMe’s Bloom Syndrome carrier test February 27, 2017Vol.41 No.08
Drugs & TargetsFree FDA approves Revlimid as maintenance in multiple myeloma following transplant February 24, 2017Vol.43 No.08
Drugs & TargetsFree Zykadia receives a Priority Review for frontline use in ALK+ metastatic NSCLC February 24, 2017Vol.43 No.08
Drugs & TargetsFree FDA accepts Mylan’s BLA for biosimilar pegfilgrastim February 24, 2017Vol.43 No.08
Drugs & TargetsFree MIODx licenses immunotherapy technologies from UCSF February 24, 2017Vol.43 No.08
Drugs & Targets Amgen submits Supplemental Biologics License Application for Blincyto February 17, 2017Vol.43 No.07
Drugs & Targets Pan-Canadian Pharmaceutical Alliance, BMS reach agreement on Opdivo February 17, 2017Vol.43 No.07
Drugs & Targets Immunomedics enters into licensing agreement with Seattle Genetics for Sacituzumab Govitecan February 17, 2017Vol.43 No.07
Drugs & Targets FDA approves Opdivo for urothelial carcinoma indication February 10, 2017Vol.43 No.06
